

Freedom of Information Request: Our Reference CTMUHB_19_24

You asked:

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following question:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Our response:

Please find below a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1st October 2023 to 31st December 2023, the latest 3 months available.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	48
Apremilast	64
Bimekizumab	18
Brodalumab	**
Certolizumab	6
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	35
Infliximab - Remicade	0
Infliximab Biosimilar	**
Ixekizumab	19

Risankizumab	51
Secukinumab	**
Tildrakizumab	14
Ustekinumab	37

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.